Bupivacaine Hydrochloride Injection Shortage Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Certain presentations of Bupivacaine Hydrochloride Injection are currently unavailable from some manufacturers due to manufacturing delays, while others remain accessible.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, BupivacaineHydrochlorideInjection.
What's in Shortage
Bupivacaine Hydrochloride Injection, with generic name Bupivacaine Hydrochloride Injection and brand names including SENSORCAINE MPF, MARCAINE, SENSORCAINE, BUPIVACAINE HYDROCHLORIDE, and BUPIVACAINE SPINAL, is in a current shortage status. It is an injection in the therapeutic category of Anesthesia. The shortage was first posted on 02/20/2018 and last updated on 04/02/2026.
Which Manufacturers Are Affected
Fresenius Kabi USA, LLC has several presentations available, such as Sensorcaine Injection 5 mg/1 mL (NDC 63323-466-37) and 2.5 mg/1 mL (NDC 63323-464-37), with a note to check wholesalers for inventory and contact info at 888-386-1300. However, some of their presentations like Sensorcaine Injection 2.5 mg/1 mL (NDC 63323-464-31) and 5 mg/1 mL (NDC 63323-466-31) are unavailable, with expected recovery TBD. Hospira, Inc., a Pfizer Company, has many presentations available, such as Bupivacaine Hydrochloride Injection 75 mg/30 mL (NDC 0409-1159-02) and 225 mg/30 mL (NDC 0409-1165-02), with contact info at 844-646-4398. But some of their presentations, like Marcaine Injection 75 mg/10 mL (NDC 0409-1582-10) and Marcaine Injection 125 mg/50 mL (NDC 0409-1587-50), are unavailable due to manufacturing delays, with estimated recovery in March 2026 and June 2026 respectively, and Bupivacaine Spinal 15 mg/2 mL (NDC 0409-3613-01) unavailable with recovery in June 2026.
Why There's a Shortage
For the affected presentations, the shortage is due to manufacturing delays as reported by the manufacturers. No specific reason was provided for other unavailable items.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist to check for availability and discuss next steps. They can also contact the relevant manufacturer using the provided contact information. Please remember that patients should consult their healthcare provider for any guidance, as this article does not provide medical advice.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (2,050 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.